• Forbion Capital Partners Management Services BV reported management changes at portfolio company RQ Bio, naming Gavin Koh chief medical officer.
• Koh previously held senior roles at AstraZeneca and GSK, leading infectious-disease programs from discovery through launch, including Evusheld.
• RQ Bio also appointed Debra Nevin as VP, head of CMC; she has 30 years’ monoclonal-antibody development and regulatory-submission experience.
• Brad Norton joined as VP, head of clinical operations; he was VP clinical operations at Gylden Pharma, with prior senior roles at AstraZeneca.
• Vicky Wheeler was named senior director, head of program management; she previously led multidisciplinary programs at Barinthus Biotherapeutics.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Forbion Capital Partners Management Services BV published the original content used to generate this news brief on October 06, 2026, and is solely responsible for the information contained therein.